Trademark prosecution data reveals how the rival healthcare companies are ensuring exclusivity internationally for their ...
Eli Lilly's profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.
Weight loss drugs are huge these days, and Eli Lilly (LLY) is leading the pack when it comes to these. However, today’s ...
Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing ...
Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.
Investor's Business Daily on MSN1d
Eli Lilly Earnings Top, 2025 Guidance Strong, But Weight-Loss Drug Sales MissEli Lilly earnings topped Q4 views with 2025 guidance above consensus, even though Zepbound and Mounjaro slightly missed. Eli Lilly stock rose.
In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...
Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback